{"protocolSection": {"identificationModule": {"nctId": "NCT03541187", "orgStudyIdInfo": {"id": "DAIT ICAC-28"}, "secondaryIdInfos": [{"id": "UM1AI114271", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/UM1AI114271"}, {"id": "NIAID CRMS ID#: 38517", "type": "OTHER", "domain": "DAIT NIAID"}], "organization": {"fullName": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "briefTitle": "Cockroach Immunotherapy in Children and Adolescents", "officialTitle": "Cockroach Immunotherapy in Children and Adolescents", "acronym": "CRITICAL"}, "statusModule": {"statusVerifiedDate": "2023-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-07-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-06-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-06-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-05-07", "studyFirstSubmitQcDate": "2018-05-17", "studyFirstPostDateStruct": {"date": "2018-05-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-02-21", "resultsFirstSubmitQcDate": "2023-05-18", "resultsFirstPostDateStruct": {"date": "2023-05-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-05-18", "lastUpdatePostDateStruct": {"date": "2023-05-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "collaborators": [{"name": "Inner-City Asthma Consortium", "class": "NETWORK"}, {"name": "Rho Federal Systems Division, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City Asthma Consortium (ICAC) is to evaluate the efficacy of cockroach immunotherapy in inner city asthma.\n\nThe primary objective of the study is to determine if the response to nasal allergen challenge (NAC) will be changed with treatment with cockroach subcutaneous immunotherapy (SCIT) treatment.", "detailedDescription": "This is a 1:1 randomized, double-masked (blind), placebo-controlled, multicenter trial with 2 treatment arms:\n\n* German Cockroach Subcutaneous Immunotherapy (SCIT) + guideline-based standard asthma care, OR\n* Placebo (for German Cockroach Subcutaneous Immunotherapy \\[SCIT\\]) + guideline-based standard asthma care\n\nEighty participants 8 to 17 years of age who are sensitized to cockroach, have asthma, and a positive cockroach Nasal Allergen Challenge (NAC) before treatment randomization will be enrolled."}, "conditionsModule": {"conditions": ["Persistent Asthma"], "keywords": ["cockroach", "immunotherapy", "inner city asthma", "subcutaneous immunotherapy (SCIT)", "Nasal Allergen Challenge (NAC)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 82, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "G. cockroach allergenic extract", "type": "EXPERIMENTAL", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.\n\n-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.", "interventionNames": ["Biological: German cockroach allergenic extract"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.\n\n-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.", "interventionNames": ["Biological: Placebo for German cockroach allergenic extract"]}], "interventions": [{"type": "BIOLOGICAL", "name": "German cockroach allergenic extract", "description": "Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).", "armGroupLabels": ["G. cockroach allergenic extract"], "otherNames": ["Blattella germanica allergenic extract"]}, {"type": "BIOLOGICAL", "name": "Placebo for German cockroach allergenic extract", "description": "Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).", "armGroupLabels": ["Placebo"], "otherNames": ["Placebo for Blattella germanica allergenic extract"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The study's primary endpoint is the mean TNSS change from baseline to 12 months, calculated as the difference between baseline and 12-month mean TNSS up to baseline responsive dose. TNSS (0-12) is the sum of three participant-assessed scores for rhinorrhea, congestion, itching, and staff-monitored sneezing, rated 0=None, 1=Mild, 2=Moderate, 3=Severe. Analysis uses ANCOVA modeling mean TNSS difference with factors for treatment arm, site, and baseline mean TNSS. Least square means (LSmeans), SEs, difference in LSmeans between treatment and placebo groups, 95% CI, and p-value are reported. A greater change in the LSmeans indicates a better outcome.", "timeFrame": "After 12 months"}], "secondaryOutcomes": [{"measure": "Number of Immunotherapy Related Adverse Events and Number of Immunotherapy Related Serious Adverse Events in the Course of Treatment.", "description": "Summary tables will present the total number of Immunotherapy related adverse event within the course of treatment.", "timeFrame": "After 12 months"}, {"measure": "Change in Area Under the Curve (AUC) Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The Total Nasal Symptom Score (TNSS) Area under the curve (AUC) will be calculated separately at baseline and 12 months for each subject using the trapezoidal rule and divided by their baseline reactive dose. TNSS (0-12) is the sum of three participant-assessed scores for rhinorrhea, congestion, itching, and staff-monitored sneezing, rated 0=None, 1=Mild, 2=Moderate, 3=Severe. Analysis uses ANCOVA modeling AUC TNSS with factors for treatment arm, site, and baseline TNSS AUC. Least square means (LSmeans), SEs, difference in LSmeans between treatment and placebo groups, 95% CI, and p-value are reported. A greater change in the LSmeans indicates a better outcome.", "timeFrame": "After 12 months"}, {"measure": "Change in 12-month Responsive Dose Between Cockroach SCIT and Placebo", "description": "The 12-month responsive dose is being calculated as the first dose that triggers a reaction of TNSS (Total Nasal Symptom Score) greater than or equal to 6 or a sneeze score of 3, whichever occurs first, in a sequence of up to 9 doses. To estimate the hazard ratio and 95% confidence interval, we are conducting an analysis using Cox regression with censoring, while controlling for the baseline responsive dose and site. Participants who do not experience a reaction before reaching the last dose will be considered right-censored.", "timeFrame": "After 12 months"}, {"measure": "Change in Log-transformed German Cockroach-specific IgE From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The difference in log-transformed German Cockroach-specific IgE between baseline and 12 months is being modeled using ANCOVA with factors for treatment arm, site, and the respective log-transformed IgE baseline as covariates. For each treatment group, we present least square means (LSmeans) and their associated standard errors (SEs). We report the difference in LSmeans between the treatment and placebo groups, along with the associated 95% confidence interval (CI) and p-value.", "timeFrame": "After 12 months"}, {"measure": "Change in Log-transformed German Cockroach-specific IgG4 From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The difference in log-transformed German Cockroach-specific IgG4 between baseline and 12 months is being modeled using ANCOVA with factors for treatment arm, site, and the respective log-transformed IgG4 baseline as covariates. For each treatment group, we present least square means (LSmeans) and their associated standard errors (SEs). We report the difference in LSmeans between the treatment and placebo groups, along with the associated 95% confidence interval (CI) and p-value.", "timeFrame": "After 12 months"}], "otherOutcomes": [{"measure": "EXPLORATORY: Composite Asthma Severity Score (CASI)-by Treatment Group", "description": "The Composite Asthma Severity Index (CASI) is a comprehensive severity scale combining multiple facets of asthma severity: impairment, risk, and treatment. The CASI score ranges from 0 to 20 points, with higher scores indicating higher levels of severity, and includes 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations.", "timeFrame": "Month 10, Month 12"}, {"measure": "EXPLORATORY: Number of Days With Asthma Symptoms-by Treatment Group", "description": "Defined by the presence of wheezing or tightness in the chest, or cough.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Number of Nights With Asthma Symptoms-by Treatment Group", "description": "Defined by participant waking up during the night due to the presence of wheezing or tightness in the chest, or cough.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Number of Days With Albuterol Use-by Treatment Group", "description": "Albuterol is a bronchodilator used for asthma control.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Number of Nights With Albuterol use-by Treatment Group", "description": "Albuterol is a bronchodilator used for asthma control.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Asthma Treatment step-by Treatment Group", "description": "Defined by medication requirements for asthma control.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Number of Asthma exacerbations-by Treatment Group", "description": "Asthma exacerbation defined as a prescribed course of systemic steroids by a clinician or initiation of a course of systemic steroids by a participant or a hospitalization during the study.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Spirometry Measurement: Forced Expiratory Volume in 1 Second (FEV1)-by Treatment Group", "description": "FEV1 is air volume exhaled in 1 second during spirometry and is a measure of asthma severity.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Comparison of Rhinitis Symptom severity-by Treatment Group", "description": "Measured using the Modified Rhinitis Symptom Utility Index.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Comparison of Rhinitis Treatment step-by Treatment Group", "description": "Defined by medication requirements for rhinitis control.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in German Cockroach-Specific Serum IgG Over Time-by Treatment Group", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin G (IgG) vs. post-baseline German cockroach-specific serum IgG. Numerator is geometric mean post-baseline IgG; denominator is baseline IgG.This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in German Cockroach-Specific Component Allergens Over time-by Treatment Group", "description": "Including but not limited to the following component allergens: Bla g 1, Bla g 2, Bla g 4, Bla g 5 and Per a 7.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in Cockroach Skin Test Reactivity Over Time-by Treatment Group", "description": "As a measure of response to cockroach immunotherapy.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in Cockroach-Specific Blocking Antibodies Over Time-by Treatment Group", "description": "To explore serum measurement(s) of in-vitro cockroach antigen binding to B-cells.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in Cockroach-Specific T Cell Response-by Treatment Group", "description": "Limited to Part A only: Peripheral blood mononuclear cells (PBMCs) will be evaluated for the magnitude and phenotype of the Cockroach (CR)-specific T cell response to CR immunotherapy.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in Peripheral Blood Mononuclear Cells (PBMCs) Gene Expression Response to Cockroach (CR) Stimulation Over Time-by Treatment Group", "description": "To identify the changes in PBMC gene expression response to cockroach stimulation over time and compare those changes between the treated (German cockroach allergenic extract ) and untreated (placebo) group.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}, {"measure": "EXPLORATORY: Change in Nasal Lavage Gene Expression Over Time-by Treatment Group", "description": "To identify the changes in nasal lavage gene expression response to cockroach stimulation over time and compare those changes between the treated (German cockroach allergenic extract ) and untreated (placebo) group.", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:Subject(s)\n\n* And/or parent guardian must be able to understand and provide informed consent;\n* Age at date of recruitment (e.g., screening): 8 to 17 years of age\n* Have a primary place of residence in one of the pre-selected recruitment census tracts (Reference: Inner-City Asthma Consortium):\n\n  --Note: Subjects who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly-funded health insurance will qualify for inclusion.\n* Have a history of persistent asthma, for a minimum of 1 year before study entry:\n\n  * A diagnosis of asthma will be defined as a report by the caretaker that the subject had a clinical diagnosis of asthma made by a clinician \u22651 year ago, resulting in a prescription of preventative asthma medication, and\n  * Must have persistent asthma as defined by the current need for at least 88 mcg fluticasone (or the equivalent of another inhaled corticosteroid) to control asthma at the time of screening.\n* At the time of randomization, the subject's asthma must be well controlled as defined by:\n\n  * A Forced Expiratory Volume in 1 second (FEV1) \u226580% predicted, and\n  * An Asthma Control Test (ACT) or Childhood Asthma Control Test (CACT) score \u226520.\n* Is sensitive to German cockroach as documented by:\n\n  * a positive (\u22653 mm greater than negative control) skin prick test result, and\n  * detectable German cockroach specific Immunoglobulin E (IgE) (\u2265 0.35 kUA/L).\n* Have no known contraindications to therapy with glycerinated German cockroach allergenic extract or placebo;\n* Have a positive cockroach nasal challenge, as defined by reaching a Total Nasal Symptom Score (TNSS) of \u22656 or a sneezing score of 3 at dose 2 or above during the challenge before randomization; and\n* Have documentation of current medical insurance with prescription coverage at randomization.\n\nExclusion Criteria:Subject(s)\n\n* Unable or unwilling to give written informed consent or comply with the study protocol;\n* That is pregnant or lactating;\n* That are post-menarcheal females must be abstinent or use a medically acceptable birth control method throughout their participation in the study (e.g. oral, subcutaneous, mechanical, or surgical contraception);\n* That cannot perform spirometry and peak flow at treatment randomization;\n* That have an asthma severity classification at the time of treatment randomization of severe persistent, using the The National Asthma Education and Prevention Program (NAEPP) classification, as evidenced by at least one of the following:\n\n  * Requires a dose \\>500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid,\n  * Has received more than 2 courses of oral or parenteral corticosteroids in the last 12 months or one course within the last 3 months prior to study entry,\n  * Has been treated with depot steroids within the 3 months prior to study entry,\n  * Has been hospitalized for asthma within the 6 months prior to study entry, or\n  * Has had a life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to study entry.\n* Does not have access to a phone (needed for scheduling appointments);\n* Has received allergen immunotherapy (Sublingual Immunotherapy \\[SLIT\\] or Subcutaneous Immunotherapy \\[SCIT\\]) in the last 12 months or, who plan to initiate or resume allergen immunotherapy during the study;\n* Has received biologic therapy (e.g., anti-Immunoglobulin E \\[IgE\\], anti-IL-4, anti-IL-5) within 6 months of study entry;\n* Has received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study;\n* Has past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may:\n\n  * pose additional risks from participation in the study,\n  * may interfere with the subject's ability to comply with study requirements, or\n  * that may impact the quality or interpretation of the data obtained from the study.\n* Who have nasal polyps or other major structural abnormalities in their nasal cavities as assessed by anterior rhinoscopy,\n* Who meet any of the following criteria are not eligible for enrollment and may not be reassessed:\n\n  * That plan to move from the area during the study period,\n  * Have a history of anaphylaxis grade 3 or higher as defined by World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System,\n  * Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that, in the opinion of the investigator, might interfere with the evaluation of the investigational product or pose additional risk to the subject,\n  * Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator,\n\n    * may pose additional risks from participation in the study,\n    * may interfere with the subject's ability to comply with study requirements,\n    * or that may impact the quality or interpretation of the data obtained from the study.\n  * Are using tricyclic antidepressants or beta-adrenergic blocker drugs (both oral and topical).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "8 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Robert Wood, MD", "affiliation": "Johns Hopkins Children's Center: Department of Allergy & Immunology", "role": "STUDY_CHAIR"}, {"name": "Edward M. Zoratti, MD", "affiliation": "Henry Ford Health System: Division of Allergy and Immunology", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Children's Hospital Colorado", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Children's National Medical Center - IMPACT DC", "city": "Washington", "state": "District of Columbia", "zip": "20010", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Ann and Robert Lurie Children's Hospital of Chicago", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Johns Hopkins University", "city": "Baltimore", "state": "Maryland", "zip": "21205", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Boston Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02118", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Henry Ford Health System: Division of Allergy and Immunology", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "St. Louis Children's Hospital: Allergy, Immunology and Pulmonary Medicine Program", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Icahn School of Medicine at Mount Sinai", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Columbia University Medical Center", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Cincinnati Children's Hospital", "city": "Cincinnati", "state": "Ohio", "zip": "45229-3039", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "University of Texas Southwestern Medical School", "city": "Dallas", "state": "Texas", "zip": "75390-8859", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Participant level data access will be made available to the public at some point in the future via the mechanism of the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.", "timeFrame": "The aim is to share data with the public within 24 months upon completion of the study.", "accessCriteria": "ImmPort public data access.", "url": "http://www.immport.org/immport-open/public/home/home"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Recruited 308 participants with the goal of enrolling 80 participants into this trial. Each participant received a 12 month treatment.", "groups": [{"id": "FG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "FG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "42"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Moved out of town", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": ">2 bursts of systemic corticosteroids for asthma during treatment period (Starting Nov 2020)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Did not meet randomization criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Potential inability to tolerate maintenance dose", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Need for dose >500 mcg of fluticasone for 6 months", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent-to-treat population with available data", "groups": [{"id": "BG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "BG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "12.1", "spread": "2.48"}, {"groupId": "BG001", "value": "12.2", "spread": "2.49"}, {"groupId": "BG002", "value": "12.1", "spread": "2.46"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Between 8 and 11 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}]}, {"title": "\u2265 12 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "34"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "37"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}]}]}, {"title": "Caretaker completed high school", "description": "Measure of Primary Caretaker completed high school", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Annual household income (<15k)", "description": "Category of annual household income that falls below $15,000 per year.", "populationDescription": "Count of participants with an annual household income that falls below $15,000 per year.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "28"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "28"}]}, {"title": "Dont Know", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Cockroach-specific IgE at Baseline", "description": "Cockroach-specific IgE Category at Baseline", "populationDescription": "Insufficient blood volume led to missing data for 2 participants.", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kUA/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "7.9", "lowerLimit": "2.4", "upperLimit": "49.2"}, {"groupId": "BG001", "value": "2.6", "lowerLimit": "0.8", "upperLimit": "12.3"}, {"groupId": "BG002", "value": "4.6", "lowerLimit": "1.5", "upperLimit": "35.2"}]}]}]}, {"title": "Cockroach-specific IgG4 at Baseline", "description": "Cockroach-specific IgG4 at screening", "populationDescription": "Insufficient blood volume led to missing data for 2 participants.", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "ng/mL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "55"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "35.0", "lowerLimit": "35.0", "upperLimit": "207.5"}, {"groupId": "BG001", "value": "35.0", "lowerLimit": "35.0", "upperLimit": "80.0"}, {"groupId": "BG002", "value": "35.0", "lowerLimit": "35.0", "upperLimit": "95.0"}]}]}]}, {"title": "NAC responsive dose at baseline", "description": "Subjects receive increasing doses of allergens, administered at defined time intervals (every 10-20 minutes) until they react to a dose. A reactive dose is determined when the Total Nasal Symptom Score exceeds 6 or if the subject sneezes 5 or more times. The Total Nasal Symptom Score (TNSS), with a possible score range of 0-12, is the sum of three participant-assessed symptom scores for rhinorrhea, nasal congestion, and nasal itching, as well as a staff-monitored sneezing count. Each symptom is rated on a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}], "categories": [{"title": "Reactive Dose 1 at NAC Baseline - 0 mcg/mL", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Reactive Dose 2 at NAC Baseline - 0.00492 mcg/mL", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Reactive Dose 3 at NAC Baseline - 0.0155 mcg/mL", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Reactive Dose 4 at NAC Baseline - 0.0490 mcg/mL", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Reactive Dose 5 at NAC Baseline - 0.155 mcg/mL", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Reactive Dose 6 at NAC Baseline - 0.489 mcg/mL", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}, {"title": "Reactive Dose 7 at NAC Baseline - 1.54 mcg/mL", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Reactive Dose 8 at NAC Baseline - 4.88 mcg/mL", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "12"}]}, {"title": "Reactive Dose 9 at NAC Baseline - 15.4 mcg/mL", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The study's primary endpoint is the mean TNSS change from baseline to 12 months, calculated as the difference between baseline and 12-month mean TNSS up to baseline responsive dose. TNSS (0-12) is the sum of three participant-assessed scores for rhinorrhea, congestion, itching, and staff-monitored sneezing, rated 0=None, 1=Mild, 2=Moderate, 3=Severe. Analysis uses ANCOVA modeling mean TNSS difference with factors for treatment arm, site, and baseline mean TNSS. Least square means (LSmeans), SEs, difference in LSmeans between treatment and placebo groups, 95% CI, and p-value are reported. A greater change in the LSmeans indicates a better outcome.", "populationDescription": "All participants who are randomized, received at least one dose of study treatment, and receive at least one dose during the 12-month NAC.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "After 12 months", "groups": [{"id": "OG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "OG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.02", "spread": "0.37"}, {"groupId": "OG001", "value": "-0.79", "spread": "0.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The comparison between arms will be conducted using an analysis of covariance (ANCOVA) model, in which the change from the baseline to the 12-month TNSS mean serves as the outcome. The ANCOVA model will incorporate factors for treatment while adjusting for both the baseline TNSS mean and site.", "pValue": "0.63", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.15", "ciUpperLimit": "0.70"}]}, {"type": "SECONDARY", "title": "Number of Immunotherapy Related Adverse Events and Number of Immunotherapy Related Serious Adverse Events in the Course of Treatment.", "description": "Summary tables will present the total number of Immunotherapy related adverse event within the course of treatment.", "populationDescription": "All participants who sign consent and undergo study procedures at Screening.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Adverse Events", "timeFrame": "After 12 months", "groups": [{"id": "OG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "OG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "42"}]}], "classes": [{"title": "Number of Immunotherapy Related Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Number of Immunotherapy Related Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change in Area Under the Curve (AUC) Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The Total Nasal Symptom Score (TNSS) Area under the curve (AUC) will be calculated separately at baseline and 12 months for each subject using the trapezoidal rule and divided by their baseline reactive dose. TNSS (0-12) is the sum of three participant-assessed scores for rhinorrhea, congestion, itching, and staff-monitored sneezing, rated 0=None, 1=Mild, 2=Moderate, 3=Severe. Analysis uses ANCOVA modeling AUC TNSS with factors for treatment arm, site, and baseline TNSS AUC. Least square means (LSmeans), SEs, difference in LSmeans between treatment and placebo groups, 95% CI, and p-value are reported. A greater change in the LSmeans indicates a better outcome.", "populationDescription": "All participants who are randomized, received at least one dose of study treatment, and receive at least one dose during the 12-month NAC.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "After 12 months", "groups": [{"id": "OG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "OG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.65", "spread": "0.33"}, {"groupId": "OG001", "value": "-0.48", "spread": "0.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.69", "statisticalMethod": "ANCOVA", "paramType": "Least Square Means Difference", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.99", "ciUpperLimit": "0.66"}]}, {"type": "SECONDARY", "title": "Change in 12-month Responsive Dose Between Cockroach SCIT and Placebo", "description": "The 12-month responsive dose is being calculated as the first dose that triggers a reaction of TNSS (Total Nasal Symptom Score) greater than or equal to 6 or a sneeze score of 3, whichever occurs first, in a sequence of up to 9 doses. To estimate the hazard ratio and 95% confidence interval, we are conducting an analysis using Cox regression with censoring, while controlling for the baseline responsive dose and site. Participants who do not experience a reaction before reaching the last dose will be considered right-censored.", "populationDescription": "All participants who are randomized, received at least one dose of study treatment, and receive at least one dose during the 12-month NAC.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "After 12 months", "groups": [{"id": "OG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "OG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"title": "Reactive Dose 1 at 12 Months - 0 mcg/mL", "measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}, {"title": "Reactive Dose 2 at 12 Months -0.00492 mcg/mL", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}, {"title": "Reactive Dose 3 at 12 Months - 0.0155mcg/mL", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}, {"title": "Reactive Dose 4 at 12 Months - 0.0490 mcg/mL", "measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}, {"title": "Reactive Dose 5 at 12 Months - 0.155 mcg/mL", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}]}, {"title": "Reactive Dose 6 at 12 Months - 0.489 mcg/mL", "measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}]}, {"title": "Reactive Dose 7 at 12 Months - 1.54mcg/mL", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "7"}]}, {"title": "Reactive Dose 8 at 12 Months - 4.88 mcg/mL", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}, {"title": "Reactive Dose 9 at 12 Months - 15.4 mcg/mL", "measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": ".51", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.42", "ciUpperLimit": "1.54", "estimateComment": "At the reactive dose of 15.4 mcg/mL after 12 months, there were 11 participants who were right-censored in the Cockroach SCIT arm and 8 participants who were right-censored in the Placebo arm."}]}, {"type": "SECONDARY", "title": "Change in Log-transformed German Cockroach-specific IgE From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The difference in log-transformed German Cockroach-specific IgE between baseline and 12 months is being modeled using ANCOVA with factors for treatment arm, site, and the respective log-transformed IgE baseline as covariates. For each treatment group, we present least square means (LSmeans) and their associated standard errors (SEs). We report the difference in LSmeans between the treatment and placebo groups, along with the associated 95% confidence interval (CI) and p-value.", "populationDescription": "All participants who are randomized, received at least one dose of study treatment, and receive at least one dose during the 12-month NAC.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Log(kuA/L)", "timeFrame": "After 12 months", "groups": [{"id": "OG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "OG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "0.20"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.91", "statisticalMethod": "ANCOVA", "paramType": "Least Square Means Difference", "paramValue": "-0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.54", "ciUpperLimit": "0.49"}]}, {"type": "SECONDARY", "title": "Change in Log-transformed German Cockroach-specific IgG4 From Baseline to 12 Months Between Cockroach SCIT and Placebo", "description": "The difference in log-transformed German Cockroach-specific IgG4 between baseline and 12 months is being modeled using ANCOVA with factors for treatment arm, site, and the respective log-transformed IgG4 baseline as covariates. For each treatment group, we present least square means (LSmeans) and their associated standard errors (SEs). We report the difference in LSmeans between the treatment and placebo groups, along with the associated 95% confidence interval (CI) and p-value.", "populationDescription": "All participants who are randomized, received at least one dose of study treatment, and receive at least one dose during the 12-month NAC.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Log(ng/mL)", "timeFrame": "After 12 months", "groups": [{"id": "OG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nGerman cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467)."}, {"id": "OG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm.\n\n-In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months.\n\nPlacebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.58", "spread": "0.22"}, {"groupId": "OG001", "value": "-6.90", "spread": "0.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least Square Means Difference", "paramValue": "5.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.77", "ciUpperLimit": "5.87"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Composite Asthma Severity Score (CASI)-by Treatment Group", "description": "The Composite Asthma Severity Index (CASI) is a comprehensive severity scale combining multiple facets of asthma severity: impairment, risk, and treatment. The CASI score ranges from 0 to 20 points, with higher scores indicating higher levels of severity, and includes 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations.", "reportingStatus": "NOT_POSTED", "timeFrame": "Month 10, Month 12", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Number of Days With Asthma Symptoms-by Treatment Group", "description": "Defined by the presence of wheezing or tightness in the chest, or cough.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Number of Nights With Asthma Symptoms-by Treatment Group", "description": "Defined by participant waking up during the night due to the presence of wheezing or tightness in the chest, or cough.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Number of Days With Albuterol Use-by Treatment Group", "description": "Albuterol is a bronchodilator used for asthma control.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Number of Nights With Albuterol use-by Treatment Group", "description": "Albuterol is a bronchodilator used for asthma control.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Asthma Treatment step-by Treatment Group", "description": "Defined by medication requirements for asthma control.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Number of Asthma exacerbations-by Treatment Group", "description": "Asthma exacerbation defined as a prescribed course of systemic steroids by a clinician or initiation of a course of systemic steroids by a participant or a hospitalization during the study.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Spirometry Measurement: Forced Expiratory Volume in 1 Second (FEV1)-by Treatment Group", "description": "FEV1 is air volume exhaled in 1 second during spirometry and is a measure of asthma severity.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Comparison of Rhinitis Symptom severity-by Treatment Group", "description": "Measured using the Modified Rhinitis Symptom Utility Index.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Comparison of Rhinitis Treatment step-by Treatment Group", "description": "Defined by medication requirements for rhinitis control.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in German Cockroach-Specific Serum IgG Over Time-by Treatment Group", "description": "Outcome is the ratio of geometric means for baseline German cockroach-specific serum Immunoglobulin G (IgG) vs. post-baseline German cockroach-specific serum IgG. Numerator is geometric mean post-baseline IgG; denominator is baseline IgG.This result is an indicator of immune modulation over time, however its clinical significance is unclear.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in German Cockroach-Specific Component Allergens Over time-by Treatment Group", "description": "Including but not limited to the following component allergens: Bla g 1, Bla g 2, Bla g 4, Bla g 5 and Per a 7.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in Cockroach Skin Test Reactivity Over Time-by Treatment Group", "description": "As a measure of response to cockroach immunotherapy.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in Cockroach-Specific Blocking Antibodies Over Time-by Treatment Group", "description": "To explore serum measurement(s) of in-vitro cockroach antigen binding to B-cells.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in Cockroach-Specific T Cell Response-by Treatment Group", "description": "Limited to Part A only: Peripheral blood mononuclear cells (PBMCs) will be evaluated for the magnitude and phenotype of the Cockroach (CR)-specific T cell response to CR immunotherapy.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in Peripheral Blood Mononuclear Cells (PBMCs) Gene Expression Response to Cockroach (CR) Stimulation Over Time-by Treatment Group", "description": "To identify the changes in PBMC gene expression response to cockroach stimulation over time and compare those changes between the treated (German cockroach allergenic extract ) and untreated (placebo) group.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "EXPLORATORY: Change in Nasal Lavage Gene Expression Over Time-by Treatment Group", "description": "To identify the changes in nasal lavage gene expression response to cockroach stimulation over time and compare those changes between the treated (German cockroach allergenic extract ) and untreated (placebo) group.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline (Pre-treatment) through Study Completion, an Average of 1 Year", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events (including SAEs) were collected from the time of obtaining informed consent until 30 days after a participant completed study participation or until 30 days after the participant prematurely withdrew or was withdrawn from the study.", "description": "The same as clinicaltrials.gov", "eventGroups": [{"id": "EG000", "title": "Cockroach SCIT", "description": "Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm. -In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months. German cockroach allergenic extract: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).", "deathsNumAffected": 0, "deathsNumAtRisk": 40, "seriousNumAffected": 2, "seriousNumAtRisk": 40, "otherNumAffected": 34, "otherNumAtRisk": 40}, {"id": "EG001", "title": "Placebo", "description": "Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 17 years of age will be randomized to this treatment arm. -In the first stage of dose escalation, up to 2 doses of the assigned SCIT treatment will be given weekly, separated by a minimum of 2 days. During the second phase of dose escalation, up to 1 dose of the assigned SCIT treatment will be given weekly, separated by a minimum of 5 days. After maintenance dose is achieved, participants will receive two additional maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months. Placebo for German cockroach allergenic extract: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).", "deathsNumAffected": 0, "deathsNumAtRisk": 42, "seriousNumAffected": 0, "seriousNumAtRisk": 42, "otherNumAffected": 35, "otherNumAtRisk": 42}], "seriousEvents": [{"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}], "otherEvents": [{"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 7, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 40, "numAffected": 11, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Injection site haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Injection site induration", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 49, "numAffected": 18, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 42}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 42}]}, {"term": "Corona virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 42}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 42}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 15, "numAffected": 10, "numAtRisk": 42}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 42}]}, {"term": "Peak expiratory flow rate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 42}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 10, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 42}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 42}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 42}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director, Clinical Research Operations Program", "organization": "DAIT/NIAID", "email": "DAITClinicalTrialsGov@niaid.nih.gov", "phone": "301-594-7669"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-01-11", "uploadDate": "2023-02-03T14:51", "filename": "Prot_000.pdf", "size": 1224130}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-06-09", "uploadDate": "2023-02-03T14:51", "filename": "SAP_001.pdf", "size": 678474}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-03-23", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M2853", "name": "Immunomodulating Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}